GNBT - pronta a explodir
23 mensagens
|Página 1 de 1
gnbt
boas,
atenção à GNBT!!!! está pronta para explodir!!
razões:
1 - nos ultimos meses formou uma boa base na cotação actual (0,64)
2 - brevemente são esperadas noticias sobre os diversos produtos que a gnbt têm.
3 - tem até ao final de abril para atingir o 1 dólar...senao...delisting do nasdaq!! será que vão deixar cair a gnbt? não creio! (mas posso estar enganado)
e .............
inside trading! 1300000 acções /opções ao preço de 0,64!!! saiu agora a noticia!! a ceo e os directores estao com a barriga cheia!!!
ah!!! e ... atenção ao mentor capital!!! quem acompanha esta acção e segue as biotechs sabe aquilo que estou a dizer! creio que estao acumular fortemente. a cotacao esta controlada!! só restam 6 semanas ate ao final de abril. contagem decrescente....
atenção à GNBT!!!! está pronta para explodir!!
razões:
1 - nos ultimos meses formou uma boa base na cotação actual (0,64)
2 - brevemente são esperadas noticias sobre os diversos produtos que a gnbt têm.
3 - tem até ao final de abril para atingir o 1 dólar...senao...delisting do nasdaq!! será que vão deixar cair a gnbt? não creio! (mas posso estar enganado)
e .............
inside trading! 1300000 acções /opções ao preço de 0,64!!! saiu agora a noticia!! a ceo e os directores estao com a barriga cheia!!!
ah!!! e ... atenção ao mentor capital!!! quem acompanha esta acção e segue as biotechs sabe aquilo que estou a dizer!
creio que estao acumular fortemente. a cotacao esta controlada!! só restam 6 semanas ate ao final de abril. contagem decrescente....- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
GNBT
Boa tarde:
hoje saiu mais uma noticia sobre a GNBT. Após um mês de Fevereiro sem qualquer noticia, a Generex já emitiu dois comunicados durante o mês de Março.
http://finance.yahoo.com/news/Generex-E ... l?x=0&.v=1
Neste momento a cotação está a 0,65 e a Generex tem até ao final do mês de Abril de atingir o 1 dolar para satisfazer os requisitos do Nasdaq.
As próximas semanas devem ser interessantes!
hoje saiu mais uma noticia sobre a GNBT. Após um mês de Fevereiro sem qualquer noticia, a Generex já emitiu dois comunicados durante o mês de Março.
http://finance.yahoo.com/news/Generex-E ... l?x=0&.v=1
Neste momento a cotação está a 0,65 e a Generex tem até ao final do mês de Abril de atingir o 1 dolar para satisfazer os requisitos do Nasdaq.
As próximas semanas devem ser interessantes!
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Olá Shevet,
Falaram sim:
A empresa está subir graças à especulação pura e dura ou, de facto, esse medicamento já foi ou tem grandes chances de ser aprovado pela FDA?
Quais outros produtos (medicamentos) esta empresa fabrica e que podem justificar essas subidas?
Shevet, o gráfico que colocaste no teu post indica que o medicamento já está no mercado. Confirma-se?
Shevet Escreveu:Ninguem falou de nenhum medicamento em especifico...
Falaram sim:
Pedro200 Escreveu:esta empresa que vai assumir num futuro próximo uma posição relevante no mercado dos diabéticos com um novo produto que está prestes a ser lançado. O que esta empresa propõe é substituir as agulhas que são utilizadas para fazer a injecção de insulina por um spray oral.
A empresa está subir graças à especulação pura e dura ou, de facto, esse medicamento já foi ou tem grandes chances de ser aprovado pela FDA?
Quais outros produtos (medicamentos) esta empresa fabrica e que podem justificar essas subidas?
Shevet, o gráfico que colocaste no teu post indica que o medicamento já está no mercado. Confirma-se?
"Es gibt keine verzweifelten Lagen, es gibt nur verzweifelte Menschen" - Heinz Guderian
Trad. "Não existem situações desesperadas, apenas pessoas desesperadas"
Cartago Technical Analysis - Blog
Trad. "Não existem situações desesperadas, apenas pessoas desesperadas"
Cartago Technical Analysis - Blog
- Mensagens: 3056
- Registado: 20/1/2008 20:32
- Localização: Lisboa
Ninguem falou de nenhum medicamento em especifico, mas aqui vai o pipeline da Generex e o da Antigen (subsidiaria da Generex.
A meu ver, é o fundo "Mentor Capital" que está a puxar por elas todas em busca de mais valias consideraveis, o facto de terem de colocar a cotação acima de 1 USD tb é um factor a ter em conta, que pode estar a ser trabalhado.
Abraço
Shevet
A meu ver, é o fundo "Mentor Capital" que está a puxar por elas todas em busca de mais valias consideraveis, o facto de terem de colocar a cotação acima de 1 USD tb é um factor a ter em conta, que pode estar a ser trabalhado.
Abraço
Shevet
- Anexos
-
- gnbtpipe1.jpg (106.43 KiB) Visualizado 1458 vezes
-
- Pipeline2009.bmp (847.45 KiB) Visualizado 1454 vezes
Estás a sentir????
O 50 Cent, looooooool
O 50 Cent, looooooool
-
- Mensagens: 911
- Registado: 14/2/2006 15:32
- Localização: Caldeirada de Enguias
A FDA já aprovou esse medicamente? Há alguma previsão de quando o mesmo será aprovado (ou não)?
No site da FDA (www.fda.gov) fiz uma pesquisa por Generex e não encontrei nada de relevante.
Ela está a subir bastante, mas há MUITA especulação à volta!
No site da FDA (www.fda.gov) fiz uma pesquisa por Generex e não encontrei nada de relevante.
Ela está a subir bastante, mas há MUITA especulação à volta!
"Es gibt keine verzweifelten Lagen, es gibt nur verzweifelte Menschen" - Heinz Guderian
Trad. "Não existem situações desesperadas, apenas pessoas desesperadas"
Cartago Technical Analysis - Blog
Trad. "Não existem situações desesperadas, apenas pessoas desesperadas"
Cartago Technical Analysis - Blog
- Mensagens: 3056
- Registado: 20/1/2008 20:32
- Localização: Lisboa
Boas Pedro, isto só alcança quem não cança!!
Como sabes a Generex tem de colocar o titulo a cotar acima de 1 USD durante pelo menos 10 dias concecutivos para continuar a cotar no Nasdaq e só o tem até 5 de Maio deste ano para o fazer.
Acima dos 0,95 só vejo 1,46 e 1,91 como resistencias mais significativas.
Vamos ver no que isto da,............então se começarem a sair aprovações......Upa Upa
Abraço
Shevet
Como sabes a Generex tem de colocar o titulo a cotar acima de 1 USD durante pelo menos 10 dias concecutivos para continuar a cotar no Nasdaq e só o tem até 5 de Maio deste ano para o fazer.
Acima dos 0,95 só vejo 1,46 e 1,91 como resistencias mais significativas.
Vamos ver no que isto da,............então se começarem a sair aprovações......Upa Upa
Abraço
Shevet
Estás a sentir????
O 50 Cent, looooooool
O 50 Cent, looooooool
-
- Mensagens: 911
- Registado: 14/2/2006 15:32
- Localização: Caldeirada de Enguias
Boas Pedro com estas noticias achas que pode chegar até onde?Estou dentro desde 0,53,mas já negociei GNBT ela fez um pique de um dia.Achas que agora ela pode ficar acima de 1 USD ou pode ser mais um pique que temos de aproveitar um abraço e bons trades
- Mensagens: 65
- Registado: 17/8/2009 20:29
- Localização: 16
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Ainda temos os 0,65 e os 0,83 pela frente, devem ser as resistencias mais relevantes. Comop suporte temos os 0,52.
Uma coisa positiva é o aumento do volume, que pode originar movimentos muito fortes e rapidos, pelo menos é o que se costuma verificar.
Abraço
Shevet
Uma coisa positiva é o aumento do volume, que pode originar movimentos muito fortes e rapidos, pelo menos é o que se costuma verificar.
Abraço
Shevet
Estás a sentir????
O 50 Cent, looooooool
O 50 Cent, looooooool
-
- Mensagens: 911
- Registado: 14/2/2006 15:32
- Localização: Caldeirada de Enguias
WORCESTER, Mass., Dec. 1, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that the Company's proprietary Crave-NX(TM) 7-Day Diet Aid Spray will soon be available in Duane Reade's 256 drugstores throughout New York City.
Related Quotes
Symbol Price Change
GNBT 0.58 0.00
{"s" : "gnbt","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Crave-NX(TM) 7-Day Diet Aid Spray is a great tasting orange-flavored formulation, sprayed and administered into the mouth, scientifically formulated to quickly curb cravings throughout the day, saving valuable calories. The product has been clinically-tested, has 20 servings per bottle, with only two calories per serving and zero fat. Crave-NX(TM) is a brand new diet aid that can help "Spray the Crave Away(TM)" while saving calories by controlling the user's sweet tooth and junk food cravings throughout the day, which can save up to 1,000 calories per day. Over a one-year period, saving just 250 calories per day adds up to over 90,000 calories -- or 26 pounds. Crave-NX(TM) is a product that is positioned to complement other diet products and/or programs, which provide incremental sales for retailers and a new diet add-on solution for the consumer.
"We are excited that Crave-NX(TM) is now being sold in Duane Reade, the largest drugstore in New York City," said Rose Perri, Generex's Chief Operating Officer. "We are backing the Crave-NX(TM) brand with an aggressive marketing campaign designed to ensure customer demand, awareness and repeat purchases. With 256 locations in New York City, one of the largest and most diverse consumer populations in the country, Duane Reade is an excellent place for Generex to begin is distribution of CraveNX."
Recently, the Company implemented a new media campaign starting with radio ads for Crave-NX(TM) 7-Day Diet Spray (www.Crave-Nx.com). The radio ad (http://www.barkerdzp.com/cravenx/) has been launched in targeted markets including New York, New Jersey, Houston, and Dallas with television advertising in major markets to follow.
According to Marketdata Enterprises, Inc. (www.marketdataenterprises.com), a leading market research publisher of service industry studies, the total U.S. weight loss market generated sales of $59 billion in 2007. It is estimated that 72 million people are dieters -- about 70% of whom try to lose weight without professional help.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
About Duane Reade
Founded in 1960, Duane Reade is the largest drug store chain in New York City. In keeping with company's brand vision of New York Living Made Easy, Duane Reade provides New Yorkers with prescriptions, health products and services, beauty products and services, and convenience items for daily life in the city ... everything for "How I Feel", "How I Look", and "What I Need Now". As of October 1, 2009, the Company operates 256 stores.
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Related Quotes
Symbol Price Change
GNBT 0.58 0.00
{"s" : "gnbt","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Crave-NX(TM) 7-Day Diet Aid Spray is a great tasting orange-flavored formulation, sprayed and administered into the mouth, scientifically formulated to quickly curb cravings throughout the day, saving valuable calories. The product has been clinically-tested, has 20 servings per bottle, with only two calories per serving and zero fat. Crave-NX(TM) is a brand new diet aid that can help "Spray the Crave Away(TM)" while saving calories by controlling the user's sweet tooth and junk food cravings throughout the day, which can save up to 1,000 calories per day. Over a one-year period, saving just 250 calories per day adds up to over 90,000 calories -- or 26 pounds. Crave-NX(TM) is a product that is positioned to complement other diet products and/or programs, which provide incremental sales for retailers and a new diet add-on solution for the consumer.
"We are excited that Crave-NX(TM) is now being sold in Duane Reade, the largest drugstore in New York City," said Rose Perri, Generex's Chief Operating Officer. "We are backing the Crave-NX(TM) brand with an aggressive marketing campaign designed to ensure customer demand, awareness and repeat purchases. With 256 locations in New York City, one of the largest and most diverse consumer populations in the country, Duane Reade is an excellent place for Generex to begin is distribution of CraveNX."
Recently, the Company implemented a new media campaign starting with radio ads for Crave-NX(TM) 7-Day Diet Spray (www.Crave-Nx.com). The radio ad (http://www.barkerdzp.com/cravenx/) has been launched in targeted markets including New York, New Jersey, Houston, and Dallas with television advertising in major markets to follow.
According to Marketdata Enterprises, Inc. (www.marketdataenterprises.com), a leading market research publisher of service industry studies, the total U.S. weight loss market generated sales of $59 billion in 2007. It is estimated that 72 million people are dieters -- about 70% of whom try to lose weight without professional help.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
About Duane Reade
Founded in 1960, Duane Reade is the largest drug store chain in New York City. In keeping with company's brand vision of New York Living Made Easy, Duane Reade provides New Yorkers with prescriptions, health products and services, beauty products and services, and convenience items for daily life in the city ... everything for "How I Feel", "How I Look", and "What I Need Now". As of October 1, 2009, the Company operates 256 stores.
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
WORCESTER, Mass., Dec. 3, 2009 (GLOBE NEWSWIRE) -- Published in the journal Diabetes, Obesity and Metabolism, an independent review of clinical trials of Generex Oral-lyn(TM) shows that the oral insulin spray has a faster onset of action and shorter duration of action than insulin delivered subcutaneously.
Related Quotes
Symbol Price Change
GNBT 0.58 0.00
The ease of use of the insulin spray formulation may increase patient acceptance and treatment compliance, thereby potentially reducing complications and improving quality of life for patients with insulin-dependent diabetes," the review authors wrote.
Generex Oral-lyn(TM) is the flagship product of Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn(TM) does not have pulmonary side effects. It is safely and efficiently delivered in pain-free, standardized doses via the Company's proprietary RapidMist(TM) device, which looks like a simple asthma inhaler, but provides complete absorption through the buccal mucosa (lining of the mouth) with no deposit in the lungs.
International Diabetes Federation guidelines identify glycemic control as a crucial factor in management of the disease, yet ensuring insulin therapy compliance can be problematic when up to one-quarter of people with diabetes have needle anxiety (Diabetes Res. Clin. Pract. 1999;46:239-46).
"Patients who are needle averse face a serious barrier to their recommended treatment," warns Generex President and CEO Anna E. Gluskin. "Generex Oral-lyn(TM) promises a pain-free alternative to injectable insulin, which is good news especially for older patients and children who find needles uncomfortable."
The clinical trials of Generex Oral-lyn(TM) include patients with Type 1 and Type 2 diabetes. Incidence of Type 1 diabetes is growing by 3 percent per year in children and adolescents, and at an alarming 5 percent per year among pre-school children. It is estimated that 70,000 children under the age of 15 develop Type 1 diabetes each year -- a rate of almost 200 children each day. Currently, an estimated 440,000 children globally live with Type 1 diabetes. Type 2 diabetes was once seen as a disease of adults, but is also growing at alarming rates in children and adolescents.
"Review of clinical trials: update on oral insulin spray formulation" was authored by Paolo Pozzilli, MD, Director of Endocrinology and Diabetes, University Campus Bio-Medico, Rome; Philip Raskin, MD, Department of Internal Medicine, Southwestern Medical Center, Dallas; and Christopher G. Parkin, MS, Carmel, Indiana. The article was published online this month in advance of print publication in Diabetes, Obesity and Metabolism. The article is available at http://tr.im/DOM09.
Related Quotes
Symbol Price Change
GNBT 0.58 0.00
The ease of use of the insulin spray formulation may increase patient acceptance and treatment compliance, thereby potentially reducing complications and improving quality of life for patients with insulin-dependent diabetes," the review authors wrote.
Generex Oral-lyn(TM) is the flagship product of Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn(TM) does not have pulmonary side effects. It is safely and efficiently delivered in pain-free, standardized doses via the Company's proprietary RapidMist(TM) device, which looks like a simple asthma inhaler, but provides complete absorption through the buccal mucosa (lining of the mouth) with no deposit in the lungs.
International Diabetes Federation guidelines identify glycemic control as a crucial factor in management of the disease, yet ensuring insulin therapy compliance can be problematic when up to one-quarter of people with diabetes have needle anxiety (Diabetes Res. Clin. Pract. 1999;46:239-46).
"Patients who are needle averse face a serious barrier to their recommended treatment," warns Generex President and CEO Anna E. Gluskin. "Generex Oral-lyn(TM) promises a pain-free alternative to injectable insulin, which is good news especially for older patients and children who find needles uncomfortable."
The clinical trials of Generex Oral-lyn(TM) include patients with Type 1 and Type 2 diabetes. Incidence of Type 1 diabetes is growing by 3 percent per year in children and adolescents, and at an alarming 5 percent per year among pre-school children. It is estimated that 70,000 children under the age of 15 develop Type 1 diabetes each year -- a rate of almost 200 children each day. Currently, an estimated 440,000 children globally live with Type 1 diabetes. Type 2 diabetes was once seen as a disease of adults, but is also growing at alarming rates in children and adolescents.
"Review of clinical trials: update on oral insulin spray formulation" was authored by Paolo Pozzilli, MD, Director of Endocrinology and Diabetes, University Campus Bio-Medico, Rome; Philip Raskin, MD, Department of Internal Medicine, Southwestern Medical Center, Dallas; and Christopher G. Parkin, MS, Carmel, Indiana. The article was published online this month in advance of print publication in Diabetes, Obesity and Metabolism. The article is available at http://tr.im/DOM09.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Proxima resistencia a 0,65
Penso que poderá ir facilmente acima de 1usd caso as noticias continuem favoraveis, até para que se mantenha no indice!! Os volumes tb tem vindo a aumentar.............
Abraço
Shevet
Penso que poderá ir facilmente acima de 1usd caso as noticias continuem favoraveis, até para que se mantenha no indice!! Os volumes tb tem vindo a aumentar.............
WORCESTER, Mass., Nov 10, 2009 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has received confirmation from The NASDAQ Stock Market that the Company will be provided with an additional 180 calendar day period to regain compliance with the Capital Market's listing maintenance requirements. Subject to the exercise of Staff discretion, the Company will regain compliance if the bid price of the Company's common stock on the Capital Market closes at $1.00 per share or more for a minimum of 10 consecutive business days before May 5, 2010.
Abraço
Shevet
- Anexos
-
- Generex.jpg (189.26 KiB) Visualizado 2456 vezes
Estás a sentir????
O 50 Cent, looooooool
O 50 Cent, looooooool
-
- Mensagens: 911
- Registado: 14/2/2006 15:32
- Localização: Caldeirada de Enguias
Ontem assinou um acordo com a Sanofi-Aventis para a exploração mundial deste produto.....
Além disso à cotação actual a empresa está muito desvalorizada.....
e a aprovação pelo FDA nos States deve estar a sair....
e as vendas na india.....
e noutros países.....
não sou médico, mas se alguém tiver uma melhor noção das potencialiddaes deste produto agradecia....
Além disso à cotação actual a empresa está muito desvalorizada.....
e a aprovação pelo FDA nos States deve estar a sair....
e as vendas na india.....
e noutros países.....
não sou médico, mas se alguém tiver uma melhor noção das potencialiddaes deste produto agradecia....
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Re: GNBT - pronta a explodir
pedro200 Escreveu:Bom dia!
neste momento não tenho muito tempo para explicar de forma fundamentada as razões da minha aposta na GNBT! (amanhã se for possível faço uma descrição exaustiva).
Mas aconselho que começam a prestar atenção a esta empresa que vai assumir num futuro próximo uma posição relevante no mercado dos diabéticos com um novo produto que está prestes a ser lançado. O que esta empresa propõe é substituir as agulhas que são utilizadas para fazer a injecção de insulina por um spray oral.
Depois dou mais detalhes....
Abraço
O spray oral já existe há imenso tempo e é incomparavelmente mais fraco e ineficiente do que a insulina, daí a sua adopção total ainda não estar realizada ..
- Mensagens: 1295
- Registado: 5/12/2007 16:26
GNBT - pronta a explodir
Bom dia!
neste momento não tenho muito tempo para explicar de forma fundamentada as razões da minha aposta na GNBT! (amanhã se for possível faço uma descrição exaustiva).
Mas aconselho que começam a prestar atenção a esta empresa que vai assumir num futuro próximo uma posição relevante no mercado dos diabéticos com um novo produto que está prestes a ser lançado. O que esta empresa propõe é substituir as agulhas que são utilizadas para fazer a injecção de insulina por um spray oral.
Depois dou mais detalhes....
Abraço
neste momento não tenho muito tempo para explicar de forma fundamentada as razões da minha aposta na GNBT! (amanhã se for possível faço uma descrição exaustiva).
Mas aconselho que começam a prestar atenção a esta empresa que vai assumir num futuro próximo uma posição relevante no mercado dos diabéticos com um novo produto que está prestes a ser lançado. O que esta empresa propõe é substituir as agulhas que são utilizadas para fazer a injecção de insulina por um spray oral.
Depois dou mais detalhes....
Abraço
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
23 mensagens
|Página 1 de 1